Catalog No.
Product Name
Application
Product Information
Citations
-
PD1 signaling pathway inhibitor
PD-1-IN-18 is a PD1 signaling pathway inhibitor, which acts as an immunomodulator. -
programmed cell death-1 (PD-1) inhibitor
PD-1-IN-17 is a programmed cell death-1 (PD-1) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nM. -
PD-1/PD-L1 interaction inhibitor
PD-1/PD-L1 inhibitor 2 is a PD-1/PD-L1 interaction inhibitor. -
Anti-PD-L1 Antibody
Avelumab is a fully human IgG1 monoclonal antibody targeting PD-L1, facilitating antibody-dependent cell-mediated cytotoxicity (ADCC). It has shown the ability to enhance ADCC in various cancer cell lines that express PD-L1. This reagent is primarily applicable in research focused on chordoma and related oncological studies. -
PD-1/PD-L1 interaction inhibitor
PD-1-IN-22 is a potent programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction inhibitor with an IC50 of 92.3 nM. -
PD-1/PD-L1 interaction inhibitor
BMS-1166 hydrochloride is a potent PD-1/PD-L1 interaction inhibitor with an IC50 of 1.4 nM. BMS-1166 antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation. -
PROTAC PD-1/PD-L1 Degrader
PROTAC PD-1/PD-L1 degrader-1 is a bifunctional degrader that targets the PD-1/PD-L1 immune checkpoint interaction by utilizing a Cereblon E3 ligase ligand. It demonstrates potent inhibitory activity with an IC50 of 39.2 nM, effectively restoring immune function in co-culture models involving liver cancer cells and CD3 T cells. Additionally, this compound reduces PD-L1 protein levels through a lysosome-dependent degradation pathway, making it a valuable tool for research in cancer immunotherapy and immune modulation. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-54 is an inhibitor of the PD-1/PD-L1 interaction, targeting immune checkpoints critical for tumor immune evasion. With a KD of 55.8 μM for PD-1 and 46.4 μM for PD-L1, and an IC50 of 88.6 μM, this compound enhances CD8+ T cell activation and promotes the secretion of key cytokines such as IFN-γ and IL-2. Furthermore, PD-1/PD-L1-IN-54 exhibits anticancer properties by inhibiting tumor cell proliferation and inducing apoptosis, while also modulating T cell immunity via the PI3K/Akt signaling pathway. -
CSE1L/PD-L1 Inhibitor
Naamidine J is an imidazole-type alkaloid that functions as a CSE1L/PD-L1 inhibitor. It demonstrates significant anti-inflammatory activity by reducing pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6, while enhancing the expression of anti-inflammatory markers like CD206 and Arg-1. Additionally, Naamidine J exhibits antitumor properties and alleviates pulmonary tissue edema and inflammatory infiltrates in murine models. This compound is valuable for research focused on the immune microenvironment in the contexts of acute lung injury and cancer. -
PD-L1/HDAC6 Inhibitor
PD-L1/HDAC6-IN-1 is a dual inhibitor targeting PD-L1 and HDAC6, effectively disrupting the PD-L1/PD-1 interaction with IC50 values of 26.8 nM and 69 nM, respectively. This compound significantly enhances the cytotoxicity of Jurkat T cells against HepG2 cells with an IC50 of 3.4 μM. Additionally, PD-L1/HDAC6-IN-1 demonstrates favorable pharmacokinetics in rat models, achieving a drug exposure level of 871.62 ng·h/mL, and shows promising antitumor efficacy in B16-F10 xenograft models in mice. -
PD-L1/HDAC Inhibitor
PD-L1/HDAC-IN-1 is a dual inhibitor targeting PD-L1, HDAC2, and HDAC3, with IC50 values of 88.10 nM, 27.98 nM, and 14.47 nM, respectively. This compound effectively disrupts the PD-1/PD-L1 interaction and demonstrates minimal cytotoxicity in MCF-7 cells (IC50=19.34 μM). PD-L1/HDAC-IN-1 enhances the expression of PD-L1 and CXCL10, thereby facilitating an anti-tumor immune response through increased T-cell recruitment into the tumor microenvironment (TME). Its unique mechanism positions it as a valuable tool for research in cancer immunotherapy. -
CYP51/PD-L1 Inhibitor
CYP51/PD-L1-IN-3 is a dual inhibitor targeting CYP51 and PD-L1, exhibiting potent antifungal activity with IC50 values of 0.205 μM and 0.039 μM, respectively. This compound induces early apoptosis in fungal cells by reducing levels of intracellular IL-2, NLRP3, and NF-κBp65 proteins. Additionally, CYP51/PD-L1-IN-3 causes mitochondrial damage and reactive oxygen species (ROS) accumulation, ultimately resulting in fungal lysis and cell death. This compound serves as a valuable tool for research in fungal infections and immune modulation. -
CYP51/PD-L1 Inhibitor
CYP51/PD-L1-IN-2 is a quinazoline compound that functions as a dual inhibitor of CYP51 and PD-L1, exhibiting IC50 values of 0.263 μM and 0.017 μM, respectively. It displays notable antifungal activity by triggering early apoptosis in fungal cells, leading to significant reductions in intracellular IL-2, NLRP3, and NF-κBp65 protein levels. Additionally, CYP51/PD-L1-IN-2 induces mitochondrial damage and reactive oxygen species (ROS) accumulation, culminating in fungal lysis and subsequent cell death. This compound is valuable for research exploring antifungal mechanisms and cancer immunotherapy. -
CYP51/PD-L1 Inhibitor
CYP51/PD-L1-IN-1 is a dual inhibitor targeting both CYP51 and PD-L1, exhibiting an IC50 of 0.884 μM for CYP51 and 0.083 μM for PD-L1. This quinazoline compound demonstrates notable antifungal activity by inducing early apoptosis in fungal cells while significantly reducing intracellular levels of IL-2, NLRP3, and NF-κBp65. Additionally, CYP51/PD-L1-IN-1 contributes to mitochondrial damage and reactive oxygen species (ROS) accumulation, ultimately leading to fungal lysis and cell death. This compound is valuable for research focused on antifungal therapies and immune modulation. -
PD-1/PD-L1 Interaction Inhibitor
PD-1/PD-L1-IN 3 is a macrocyclic peptide that acts as a selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions. By binding to PD-L1, it effectively disrupts the binding of PD-L1 to PD-1 and CD80, exhibiting IC50 values of 5.60 nM and 7.04 nM, respectively. This compound is valuable for research in various fields, particularly in cancer immunotherapy and the study of infectious diseases. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-10 is a potent orally active inhibitor of the PD-1/PD-L1 interaction, with an IC50 value of 2.7 nM. This compound exhibits significant anticancer efficacy by blocking the immune checkpoint pathway, thereby enhancing T-cell activation and promoting anti-tumor responses. PD-1/PD-L1-IN-10 is valuable for research in immunotherapy and cancer treatment studies. -
PD-L1 Inhibitor
PD-L1-IN-1 is a potent inhibitor targeting programmed cell death ligand 1 (PD-L1) with an IC50 of 115 nM. It effectively disrupts the PD-L1 and PD-1 interaction, enhancing antitumor immune responses in co-cultures of PD-L1 expressing cancer cells and peripheral blood mononuclear cells. Additionally, PD-L1-IN-1 demonstrates low cytotoxicity towards healthy cells, making it a valuable tool for immunological research and therapeutic applications in cancer treatment. -
PD-1/PD-L Complex Inhibitor
BMS-202 hydrochloride is a potent inhibitor of the PD-1/PD-L1 complex, exhibiting an IC50 of 18 nM and a KD of 8 μM. This nonpeptidic molecule selectively binds to PD-L1, effectively blocking the interaction between human PD-1 and PD-L1. BMS-202 hydrochloride demonstrates significant antitumor activity, making it a valuable tool for research in immunotherapy and cancer biology. -
PD-L1 Inhibitor
INCB086550 is a potent oral small-molecule inhibitor of PD-L1, exhibiting IC50 values of 3.1, 4.9, and 1.9 nM for human, cynomolgus, and rat PD-L1, respectively. This compound promotes the dimerization of cell-surface PD-L1 and facilitates its entry into Golgi vesicles, leading to nuclear trafficking. INCB086550 is primarily used in cancer research, particularly in studies focusing on immune checkpoint regulation and tumor microenvironment modulation. -
PD-1/PD-L1 Interaction Inhibitor
PD-1/PD-L1-IN-9 is a potent inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 value of 3.8 nM. This compound enhances the antitumor activity of immune cells against tumor cells. Additionally, PD-1/PD-L1-IN-9 demonstrates significant in vivo antitumor efficacy in the CT26 mouse model, making it a valuable tool for cancer immunotherapy research. -
PD-L1 Inhibitor
BMS-986189 is a macrocyclic peptide that functions as a highly potent PD-L1 inhibitor, demonstrating an IC50 of 1.03 nM in disrupting the PD-1/PD-L1 interaction. This compound is suitable for cancer research applications, particularly in studies involving human lung carcinoma cells such as L2987, making it valuable for exploring immune checkpoint mechanisms and developing novel therapeutic strategies. -
PD-1/PD-L1 Inhibitor
BMS-8 is a selective inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 of 7.2 μM. It directly binds to PD-L1, promoting the formation of PD-L1 homodimers, thereby obstructing the engagement with PD-1. This compound is primarily utilized in cancer immunotherapy research, particularly in studies focused on the modulation of immune checkpoint pathways. -
PD-L1 Binding Peptide
WL12 is a PD-L1 binding peptide that specifically targets the programmed death ligand 1. This peptide can be radiolabeled with various radionuclides to create radiotracers, facilitating the assessment of PD-L1 expression in tumors. It is a valuable tool for cancer research, particularly in studies focused on immune checkpoint blockade and tumor immunology. -
PD-1/PD-L1 PPI Inhibitor
Evixapodlin is a potent inhibitor of the PD-1/PD-L1 protein-protein interaction, exhibiting an IC50 of 0.213 nM. This compound demonstrates significant anticancer and antiviral activities, making it a valuable tool for research in immunotherapy and viral pathogenesis. Evixapodlin is particularly useful for studying the modulation of immune responses in tumor environments and understanding the interplay between immune checkpoints and viral infections. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-14 is a bifunctional inhibitor specifically targeting the PD-1/PD-L1 interaction, exhibiting an IC50 of 27.8 nM. This compound effectively disrupts PD-1/PD-L1 binding while promoting the dimerization, internalization, and degradation of PD-L1. Its unique mechanism of action supports research in immunotherapy and cancer treatment, making it a valuable tool for studies involving immune modulation and T-cell activation. -
PD-L1 Inhibitor
PD-L1-IN-3 is a PD-L1 inhibitor that effectively targets the PD-1/PD-L1 interaction. With an IC50 value of 4.97 nM for inhibiting PD-L1 and an EC50 value of 2.70 μM for Jurkat T cell activation, this compound disrupts PD-1 signaling by binding to the PD-L1 dimer. PD-L1-IN-3 is particularly valuable for research applications in lung cancer and melanoma, facilitating the study of immune checkpoint mechanisms in these diseases. -
PD-1/PD-L1 Inhibitor
MAX-10181 is a selective inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 value of 0.018 μM. This compound is instrumental in cancer research, facilitating the exploration of immune checkpoint blockade mechanisms and potential therapeutic applications in oncology and related diseases. Researchers can utilize MAX-10181 to study the modulation of immune responses in various tumor models. -
PD-1/PD-L1 Inhibitor
ARB-272572 is a potent small molecule inhibitor targeting the PD-L1 pathway, exhibiting an IC50 value of 400 pM. This compound enhances antitumor immunity and shows promise in the treatment of chronic viral infections. ARB-272572 is valuable for research applications focused on cancer immunotherapy and viral infection studies. -
PD-L1/TGF β Fusion Protein
SHR-1701 (Retlirafusp alfa) is a bifunctional fusion protein that targets programmed death-ligand 1 (PD-L1) and transforming growth factor-beta (TGF-β). This compound is designed to enhance anti-tumor immunity by concurrently inhibiting immune checkpoint pathways and modulating the tumor microenvironment. SHR-1701 is valuable for research applications focused on cancer immunotherapy and the modulation of TGF-β signaling in various malignancies. -
PD-L1 Antagonist
CVARARTR is a potent antagonist of programmed cell death ligand-1 (PD-L1) with a dissociation constant (KD) of 281 nM. It promotes the internalization of PD-L1, leading to a decrease in its surface expression. This mechanism effectively restores cytokine secretion and enhances T cell proliferation in CT26 cells. Additionally, CVRARTR demonstrates antitumor efficacy in the CT26 homograft mouse model, making it a valuable tool for research in melanoma and immunotherapy studies. -
PD-1/PD-L1 Inhibitor
N-deacetylated BMS-202 is a potent inhibitor of the PD-1/PD-L1 interaction. This compound plays a significant role in cancer immunotherapy by blocking the immune checkpoint pathway, thereby enhancing T-cell responses against tumor cells. Its application in research encompasses the investigation of tumor microenvironments and the evaluation of immune evasion mechanisms in various cancer types. -
PD-L1/PD-1 Inhibitor
BMS-1001 hydrochloride is an orally active inhibitor of the PD-L1/PD-1 immune checkpoint pathway. It demonstrates low cytotoxicity across various cell lines, making it suitable for research applications. The compound has an IC50 value of 2.25 nM in homogeneous time-resolved fluorescence (HTRF) binding assays, indicating potent inhibition of PD-1 interactions. BMS-1001 is useful for studies focused on cancer immunotherapy and the modulation of immune responses. -
PD-1/PD-L1 Inhibitor
ASC-69 is a potent inhibitor of the PD-1/PD-L1 pathway, which plays a critical role in immune evasion by tumors. This small-molecule compound demonstrates strong biological activity in inhibiting the interaction between PD-1 and PD-L1, thereby enhancing T-cell responses against cancer cells. ASC-69 is relevant for research applications focused on cancer immunotherapy and the modulation of immune checkpoint mechanisms. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-33 is a potent inhibitor of the PD-1/PD-L1 interaction, demonstrating an IC50 of 6.3 nM. This compound enhances T-cell proliferation, activation, and infiltration into tumor microenvironments, thereby exerting immunomodulatory and anticancer effects. PD-1/PD-L1-IN-33 is applicable in research focused on cancer immunotherapy and the modulation of immune responses. -
PD-L1 Inhibitor
BMS-986238 is an orally active macrocyclic peptide that functions as a PD-L1 inhibitor. This compound exhibits significant anti-tumor activity by blocking the PD-1/PD-L1 interaction, enhancing immune responses against cancer cells. BMS-986238 is utilized in research applications focusing on solid tumors and lymphomas, providing insights into immune checkpoint modulation. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-23 is a potent, orally active inhibitor of the PD-1/PD-L1 interaction. As an ester proagent of L7, a benzo[c][1,2,5]oxadiazole derivative, it has been evaluated for its ability to inhibit PD-L1. This compound demonstrates significant antitumor effects in various tumor models, including syngeneic and PD-L1 humanized mice, making it a valuable tool for cancer research and the development of immune checkpoint therapies. -
PD-L1 Inhibitor
PD-L1-IN-2 is an inhibitor of the programmed death-ligand 1 (PD-L1) pathway, functioning as a potential immunotherapeutic agent against tumors. This Naamidine J derivative demonstrates significant antitumor activity by downregulating PD-L1 expression, thereby enhancing T-cell infiltration and activity within tumors. PD-L1-IN-2 is applicable in preclinical research focused on colorectal cancer and other malignancies where PD-L1 plays a critical role in immune evasion. -
PD-1/PD-L1 Interaction Inhibitor
BMSpep-57 is a competitive macrocyclic peptide inhibitor targeting the PD-1/PD-L1 interaction, exhibiting an IC50 of 7.68 nM. It demonstrates strong binding affinity to PD-L1, with Kd values of 19 nM in Microscale Thermophoresis (MST) and 19.88 nM in Surface Plasmon Resonance (SPR) assays. By disrupting this interaction, BMSpep-57 enhances T cell function, leading to increased IL-2 production in peripheral blood mononuclear cells (PBMCs). This compound is valuable for research applications related to immunotherapy and T cell activation. -
PD-1/PD-L1 Inhibitor
Kaempferol-7-O-rhamnoside is a potent inhibitor of the PD-1/PD-L1 pathway and an agonist of the farnesoid X receptor (FXR). It exhibits cardioprotective properties by targeting the AMPKα1 signaling pathway, significantly enhancing mRNA expression of AMPKα1 in H9c2 cardiomyocytes. Additionally, Kaempferol-7-O-rhamnoside effectively reverses acetaminophen-induced reductions in glutathione levels and mitigates reactive oxygen species production in L02 cells. This compound demonstrates potential applications in research related to heart failure and oxidative stress. -
PD-1 Inhibitor
PD-1-IN-24 is a potent inhibitor of the programmed cell death protein 1 (PD-1) pathway, demonstrating robust oral bioavailability. This compound effectively modulates immune responses by blocking PD-1 interaction with its ligands, which is crucial for enhancing anti-tumor immunity. PD-1-IN-24 is utilized in research to investigate immune regulation and develop cancer immunotherapies. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-29 is a potent inhibitor of the PD-1/PD-L1 pathway, exhibiting an IC50 value of 6.1 nM. This compound effectively binds to PD-L1 to disrupt PD-1/PD-L1 interactions, facilitating PD-L1 dimerization and subsequent internalization, while enhancing its localization to the endoplasmic reticulum. PD-1/PD-L1-IN-29 demonstrates significant anticancer activity, making it a valuable tool for research in immuno-oncology and therapeutic applications targeting immune checkpoint pathways. -
PD-1/PD-L1 Inhibitor
BMS-37 is a potent PD-1/PD-L1 immune checkpoint inhibitor, demonstrating an IC50 ranging from 18 to 200 nM against the PD-L1/PD-1 complex. This compound exhibits significant toxicity toward modified Jurkat T cells, with an EC50 between 3 and 6 µM. BMS-37 is valuable for investigating PD-L1-mediated T-cell exhaustion and serves as a PD-L1 ligand in the synthesis of PROTAC molecules for targeted protein degradation studies. -
PD-1/PD-L1 Interaction Inhibitor
BMS-200 is a potent inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 of 80 nM. This compound effectively disrupts the binding of PD-L1 to PD-1, which is critical in regulating immune responses. BMS-200 is valuable for research in cancer immunotherapy, particularly in elucidating mechanisms of immune checkpoint modulation. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-NP19 is a potent inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 of 12.5 nM. This compound is designed to enhance immune responses within the tumor microenvironment, potentially leading to significant antitumor activity. It is a valuable tool for researchers investigating immunotherapy and the modulation of immune checkpoints in cancer therapy. -
PD-1 Agonist
H-20 is a potent PD-1 agonist that modulates immune responses by enhancing programmed cell death protein 1 signaling. This compound demonstrates significant biological activity in research related to chronic pain and immune regulation. Its applications extend to investigating the therapeutic potential of PD-1 activation in managing pain conditions and understanding the underlying mechanisms involved in chronic inflammatory responses.
